Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges

被引：8
作者：
Ceresoli, Giovanni Luca [1 ]
Bonomi, Maria [1 ]
Sauta, Maria Grazia [1 ]
机构：
[1] Clin Humanitas Gavazzeni, Thorac & GU Oncol Unit, Dept Med Oncol, I-24125 Bergamo, Italy
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2016年 / 16卷 / 07期
关键词：
Malignant pleural mesothelioma; immunotherapy; immune-checkpoint inhibitors; SINGLE-ARM; OPEN-LABEL; TREMELIMUMAB; CISPLATIN; BLOCKADE; PHASE-2; CANCER; SAFETY;
D O I：
10.1080/14737140.2016.1191951
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：673 / 675
页数：3
相关论文
共 50 条
  • [21] Immunotherapy in malignant pleural mesothelioma: a review of literature data
    Menis, Jessica
    Pasello, Giulia
    Remon, Jordi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (06) : 2988 - 3000
  • [22] A catalogue of treatment and technologies for malignant pleural mesothelioma
    Schunselaar, Laurel M.
    Quispel-Janssen, Josine M. M. F.
    Neefjes, Jacques J. C.
    Baas, Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 455 - 463
  • [23] The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
    Banerji, Shantanu
    Meyers, Daniel E.
    Harlos, Craig
    Dawe, David E.
    CURRENT ONCOLOGY, 2021, 28 (06) : 4542 - 4551
  • [24] Nivolumab plus ipilimumab in malignant pleural mesothelioma
    Travert, Camille
    Tomasini, Pascale
    Greillier, Laurent
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) : 815 - 822
  • [25] Tumor Microenvironment-Associated Immune-Related Genes for the Prognosis of Malignant Pleural Mesothelioma
    Xu, Xiaoling
    Cheng, Lei
    Fan, Yun
    Mao, Weimin
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [26] LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study
    Arimura, Ken
    Hiroshima, Kenzo
    Nagashima, Yoji
    Nakazawa, Tadao
    Ogihara, Akira
    Orimo, Mami
    Sato, Yasuto
    Katsura, Hideki
    Kanzaki, Masato
    Kondo, Mitsuko
    Tagaya, Etsuko
    BMC CANCER, 2023, 23 (01)
  • [27] LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study
    Ken Arimura
    Kenzo Hiroshima
    Yoji Nagashima
    Tadao Nakazawa
    Akira Ogihara
    Mami Orimo
    Yasuto Sato
    Hideki Katsura
    Masato Kanzaki
    Mitsuko Kondo
    Etsuko Tagaya
    BMC Cancer, 23
  • [28] Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
    Gounant, Valerie
    Brosseau, Solenn
    Zalcman, Gerard
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [29] Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma
    Moro, Jacopo
    Sobrero, Simona
    Cartia, Carlotta Francesca
    Ceraolo, Simona
    Rapana, Roberta
    Vaisitti, Federico
    Ganio, Stefano
    Mellone, Federica
    Rudella, Stefano
    Scopis, Federico
    La Paglia, Danilo
    Cacciatore, Carola Crystel
    Ruffini, Enrico
    Leo, Francesco
    DIAGNOSTICS, 2022, 12 (12)
  • [30] Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity
    Zarifa, Abdulrazzak
    Lopez-Mattei, Juan
    Palaskas, Nicolas
    Iliescu, Cezar
    Durand, Jean-Bernard
    Kim, Peter Y.
    IMMUNOTHERAPY, 3RD EDITION, 2020, 1244 : 277 - 285
12345